Key result
Actual body surface area-based lipophilic chemotherapy shows no increased haematological toxicity in obese versus non-obese patients.
Why the study?
The relation between obesity and haematological toxicities after lipophilic chemotherapy given according to actual body surface area in breast cancer patients was unclear.
Does lipophilic chemotherapy given according to actual body surface area increase haematological toxicity or worsen survival in obese breast cancer patients compared to normal/underweight patients?
Cohort (n=419)
No
Does lipophilic chemotherapy given according to actual body surface area increase haematological toxicity or worsen survival in obese breast cancer patients compared to normal/underweight patients?
p-value: p=0.033
Dosing lipophilic chemotherapy according to actual body surface area in obese breast cancer patients does not increase haematological toxicity or worsen survival.
No takes yet. Share an insight, caveat, or question.
May support actual BSA dosing without excess toxicity in obese breast cancer; leaves open survival effects and requires prospective validation.
Duygu Bayir Garbioglu (2023) conducted a cohort in Breast cancer (n=419). Obesity (BMI ≥30 kg/m²) vs. Normal/underweight and overweight patients was evaluated on Haematological toxicity (neutropenia, thrombocytopenia, anemia) after first course of lipophilic chemotherapy (p=0.033). Obese breast cancer patients receiving lipophilic chemotherapy based on actual body surface area did not experience increased haematological toxicity compared to normal or underweight patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: